 |
|
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
May 23, 20082 Penn studies show drug-eluting stents outperform bare metal stents
(PHILADELPHIA) - The more than ten million Americans who've received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.
The findings, among the first large follow-up studies to show a clear, lifesaving benefit of drug-eluting stents compared to bare metal stents, will be published in the May 27 issue of the Journal of the American College of Cardiology. Patients with the drug-coated stents -- designed not only to open blocked coronary arteries but also to chemically inhibit future blockage -- were less apt to die, have heart attacks or require extra stents or bypass surgery in the two years following placement of the stent.
"This might be a hidden nugget of goodness that could not be detected in clinical trials," says Peter W. Groeneveld, MD, MS, assistant professor in Penn's Division of General Internal Medicine. "There is a distinct possibility that drug-eluting stents not only reduce the need for future cardiac procedures, but also save lives."
Groeneveld and his colleagues studied Medicare data to identify about 72,000 patients who received drug-eluting stents during a nine-month period in 2003, the first year the devices were approved for use in the United States. Overall, the findings showed a clear survival benefit compared to a control group of patients who got bare metal stents -- at 90 days, 1 year and 2 years, patients with drug-coated stents were less likely to die.
In a separate study which will be published in the June issue of the American Heart Journal, Groeneveld also found that drug-eluting stents also offer cost savings during the first year after placement. Although the initial cost of the device - averaging $16,000 -- outpaces that of a bare metal stent, which costs about $14,000, the Penn researchers found that among patients with the drug-coated stents, 12 percent of those studied needed additional stents placed in the first year, compared to 15 percent of patients who received bare-metal stents. Few patients in either arm required bypass surgery in the first year following stent placement, but those who received bare-metal stents were twice as likely to need the procedure, leading to an additional cost savings of $714 per patient treated with drug-coated stents. Overall, researchers found that patients with drug-eluting stents each saved an average of $1,350 worth of follow-up care during the year, which projects a total savings of approximately $100 million dollars among the 72,000 drug-eluting stent patients studied.
The researchers note that future studies should focus on how drug therapies including clopidogrel and cholesterol-reducing statin drugs may play a role in outcomes and costs for both types of stent patients. Since recent evidence shows that clopidogrel therapy -- aimed at reducing the risk of blood clots following stent placement -- is an essential step for reducing "late" drug-eluting stent complications or failure, Groeneveld theorizes that clinical outcomes for drug-eluting stent patients might be boosted even further when patients follow an appropriate long-term drug regimen.
University of Pennsylvania School of Medicine
"This might be a hidden nugget of goodness that could not be detected in clinical trials," says Peter W. Groeneveld, MD, MS, assistant professor in Penn's Division of General Internal Medicine. "There is a distinct possibility that drug-eluting stents not only reduce the need for future cardiac procedures, but also save lives."
Groeneveld and his colleagues studied Medicare data to identify about 72,000 patients who received drug-eluting stents during a nine-month period in 2003, the first year the devices were approved for use in the United States. Overall, the findings showed a clear survival benefit compared to a control group of patients who got bare metal stents -- at 90 days, 1 year and 2 years, patients with drug-coated stents were less likely to die.
In a separate study which will be published in the June issue of the American Heart Journal, Groeneveld also found that drug-eluting stents also offer cost savings during the first year after placement. Although the initial cost of the device - averaging $16,000 -- outpaces that of a bare metal stent, which costs about $14,000, the Penn researchers found that among patients with the drug-coated stents, 12 percent of those studied needed additional stents placed in the first year, compared to 15 percent of patients who received bare-metal stents. Few patients in either arm required bypass surgery in the first year following stent placement, but those who received bare-metal stents were twice as likely to need the procedure, leading to an additional cost savings of $714 per patient treated with drug-coated stents. Overall, researchers found that patients with drug-eluting stents each saved an average of $1,350 worth of follow-up care during the year, which projects a total savings of approximately $100 million dollars among the 72,000 drug-eluting stent patients studied.
The researchers note that future studies should focus on how drug therapies including clopidogrel and cholesterol-reducing statin drugs may play a role in outcomes and costs for both types of stent patients. Since recent evidence shows that clopidogrel therapy -- aimed at reducing the risk of blood clots following stent placement -- is an essential step for reducing "late" drug-eluting stent complications or failure, Groeneveld theorizes that clinical outcomes for drug-eluting stent patients might be boosted even further when patients follow an appropriate long-term drug regimen.
University of Pennsylvania School of Medicine
Stents News and Current Stents Events RSSDES: New elements in the debate
Results announced at the 2006 ESC meeting in Barcelona questioned the long-term safety of drug eluting stents (DES) and sparked intense discussion.
Best use of drug-eluting stents
Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction.
Tiny 3-D ultrasound probe guides catheter procedures
An ultrasound probe small enough to ride along at the tip of a catheter can provide physicians with clearer real-time images of soft tissue without the risks associated with conventional x-ray catheter guidance.
Still puzzling: Best care for the frail and elderly with coronary artery disease
A new study from Duke University Medical Center finds that patients treated solely with medications after suffering from chest pain, heart attack or coronary artery disease are more likely to die during the first year following their initial hospitalization.
NYC first: Complex aneurysm treated using new fenestrated endograft stent
In a New York City metro-area first, a 93-year-old Bronx man underwent implantation of a new stent graft at NewYork-Presbyterian Hospital, the only center on the Eastern Seaboard with access to this investigational device.
New paradigm for cell-specific gene delivery
Researchers from Northwestern University and Texas A & M University have discovered a new way to limit gene transfer and expression to specific tissues in animals.
Landmark study reveals superiority of bivalirudin in heart attack patients at 30 days
The Cardiovascular Research Foundation (CRF) announced today that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.
Bypass not to blame for heart patients' mental decline
Heart patients often experience lasting problems with memory, language, and other cognitive skills after bypass surgery. However, these problems aren't caused by the surgery itself or the pump used to replace heart function during surgery, a new study by Johns Hopkins researchers suggests.
MIT crafts bacteria-resistant films
Having found that whether bacteria stick to surfaces depends partly on how stiff those surfaces are, MIT engineers have created ultrathin films made of polymers that could be applied to medical devices and other surfaces to control microbe accumulation.
In blood vessel stents, innovative materials allow better control, delivery of gene therapy
Before gene therapy becomes practical for treating human diseases, researchers must master the details of safe and effective delivery.
More Stents News Articles
 | The Double Helix: A Personal Account of the Discovery of the Structure of DNA (Norton Critical Editions) by James D. Watson "Science seldom proceeds in the straightforward logical manner imagined by outsiders," writes James Watson in The Double Helix, his account of his codiscovery (along with Francis Crick) of the structure of DNA. Watson and Crick won Nobel Prizes for their work, and their names are memorized by biology students around the world. But as in all of history, the real story behind the deceptively simple... |
 | The Global Politics of Energy by Jeffrey Bader, Stephen Biegun, Ivo Bozon, Diana Farrell, Jay Gulledge, Robert Hefner, John Podesta, Dennis Ross, David Rothkopf, Angela Stent, David Victor, Daniel Yergin Aspen policy books is a series devoted to developing critical new thinking on U.S. national security policy. This book is a collection of papers prepared for the 2007 Aspen Strategy Group conference on The Global Politics of Energy. This cross-disciplinary and high-level examination of policy strategies for addressing the challenges posed by the soaring demand for oil, the rise of petro-powers,... |
 | Russia and Germany Reborn by Angela Stent The relationship between Russia and Germany has been pivotal in some of the most fateful events of the twentieth century: the two World Wars, the Cold War, and the emergence of a new Europe from the ashes of communism. This is the first book to examine the recent evolution of that tense and often violent relationship from both the Russian and German perspectives. Angela Stent combines interviews... |
 | Congenital Heart Disease: The Catheterization Manual This manual provides a comprehensive overview of how the cardiac catheterization laboratory in a pediatric cardiology division works. Chapters are organized in the order in which a case progresses. Specific types of cases are discussed in detail and hemodynamics is covered in depth. Information tables and line illustrations are used throughout the text to further emphasize important concepts and... |
 | Urethral Reconstructive Surgery (Current Clinical Urology) (Current Clinical Urology) Urethral reconstructive surgery can often be complex, time consuming and demanding. Enlightening urologists in a practical manner, Urethral Reconstructive Surgery evaluates and manages complex urethral problems. Written by a panel of experts in the field, Urethral Reconstructive Surgery offers the anatomy of the urethra and the aspects of wound healing and applicable plastic surgical techniques.... |
| Carotid Artery Stenting: Current Practice and Techniques Written by internationally recognized experts in interventional cardiology, this comprehensive clinical reference on carotid artery stenting provides illustrated, step-by-step descriptions of techniques and details on indications, contraindications, patient selection, complications, technology, and clinical trials. The first section reviews clinical results and experience, including the CAVATAS... | |
 | Thoracic Aortic Diseases Thoracic Aortic Diseases represents an ambitious undertaking by a large number of highly respected international specialists in aortic pathologies, with the purpose of providing information on the acquired and genetic basis of aortic diseases as well as a global perspective on therapeutic alternatives. The new concept of a team approach with surgeons working together with both interventional... |
 | Phage And the Origins of Molecular Biology, The Centennial Edition This hugely influential book, published in 1966 as a 60th birthday tribute to Max Delbrück, is now republished as The Centennial Edition. On first publication, the book was hailed as "[introducing] into the literature of science, for the first time, a self conscious historical element in which the participants in scientific discovery engage in writing their own chronicle. As such, it is an... |
 | Atlas of Interventional Cardiology (Atlas of Heart Diseases (Unnumbered).) (Atlas of Heart Diseases (Unnumbered).) This 2nd ED of the atlas is a reflection of the most recent advances and changes in both techniques and devices. This atlas includes an overview of the coronary arterial response to injury as well as invasive lesion assessment, specifically coronary physiologic assessment and intravascular ultrasound. With more than 500 illustrations, clinical photographs, instructive diagrams, and charts, this... |
 | Colombo's Tips & Tricks for Drug Eluting Stents by Antonio Colombo, Goran Stankovic A trailblazer in interventional cardiology, Dr. Antonio Colombo combines his vast experience with that of Goran Stankovic and distinguished colleagues to share tips and tricks for dealing with diseased coronary arteries. Whether discussing his 'crushing and kissing' techniques or the stenting of tortuous vessels in the elderly, Dr. Colombo and his colleagues' texts and case commentaries provide... |
| © 2008 BrightSurf.com |